NCT01504321

Polycystic Ovary Syndrome - Improving Outcomes

Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Baker Heart and Diabetes Institute · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Polycystic ovary syndrome affects a striking 9-18% of Australian reproductive aged women and has been associated with a number of metabolic abnormalities. Given the strong correlation between metabolic abnormalities and increased sympathetic activity, we hypothesise that reducing this activity using medication (moxonidine) can help improve the metabolic abnormalities, and therefore improve outcomes in polycystic ovary syndrome.

Conditions

• Polycystic Ovary Syndrome

Interventions

Type	Name	Description
DRUG	Moxonidine	0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
DRUG	Placebo	Encapsulated lactose powder

Timeline

• Start date: 2012-05-01
• Primary completion: 2015-05-01
• Completion: 2015-12-01
• First posted: 2012-01-05
• Last updated: 2018-11-02

Locations

1 site across 1 country: Australia